Opposing effects of CTLA4-Ig and anti-CD80 (B7-1) plus anti-CD86 (B7-2) on experimental allergic encephalomyelitis

Peter J. Perrin*, Dorothy Scott, Tiffany A. Davis, Gary S. Gray, Michael J. Doggett, Ryo Abe, Carl H. June, Michael K. Racke, Thomas Davis

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

42 Scopus citations


The roles of the B7 receptors, CD80 and CD86, during actively induced experimental allergic encephalomyelitis were examined with specific monoclonal antibodies and CTLA4-Ig. Injection of CTLA4-Ig on day 2 post-immunization resulted in decreased incidence and severity of resultant disease. Anti-CD80 injection on day 2 blocked development of the first disease episode, Subsequent relapses were unaffected. In contrast, injection of anti-CD86 alone had no effect. Surprisingly, combined anti-CD80 + anti-CD86 monoclonal antibody injection on day 2 resulted in marked exacerbation of disease. Examination of cytokine production in the draining lymph node cells demonstrated a reduction in both interferon (IFN)-γ and interleukin (IL)-2 producing cells, but a dramatic increase in tumor necrosis factor (TNF)-α secretion in animals receiving both monoclonal antibodies. These results suggest distinct roles for CD80 and CD86 in the initiation of EAE, resulting in the diverse clinical outcomes observed in this model of EAE.

Original languageEnglish
Pages (from-to)31-39
Number of pages9
JournalJournal of Neuroimmunology
Issue number1
StatePublished - Mar 1996


  • B7 receptors
  • CD80
  • CD86
  • CTLA-4
  • Experimental allergic encephalomyelitis
  • Interferon-γ
  • Interleukin-10
  • Interleukin-2
  • Tumor necrosis factor-


Dive into the research topics of 'Opposing effects of CTLA4-Ig and anti-CD80 (B7-1) plus anti-CD86 (B7-2) on experimental allergic encephalomyelitis'. Together they form a unique fingerprint.

Cite this